IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.

被引：0
|
作者：
Starodub, Alexander
Ocean, Allyson J.
Guarino, Michael J.
Picozzi, Vincent J.
Thomas, Salim Samuel
Messersmith, Wells A.
Shah, Manlsh A.
Vandat, Linda T.
Chuang, Ellen
Lin, Bruce S.
Govindan, Serengulam V.
Maliakal, Pius P.
Wegener, William A.
Hamburger, Steven A.
Sharkey, Robert M.
Goldenberg, David M.
机构：
[1] Indiana Univ, Hlth Goshen Ctr Canc Care, Goshen, IN USA
[2] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[3] Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA
[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[5] Univ Florida, Hlth Canc Ctr, Orlando Hlth, Orlando, FL USA
[6] Univ Colorado Denver, Div Med Oncol, Aurora, CO USA
[7] Weill Cornell Med Coll, New York, NY USA
[8] Immunomedics Inc, Morris Plains, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.3032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3032
引用
收藏
页数：1
相关论文
共 44 条
  • [21] IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)
    Bardia, Aditya
    Starodub, Alexander
    Moroose, Rebecca L.
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Chuang, Ellen
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Maliakal, Pius
    Wegener, William A.
    Hamburger, Steven A.
    Ocean, Allyson J.
    Goldenberg, David M.
    Vahdat, Linda T.
    CANCER RESEARCH, 2015, 75
  • [22] Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Cardillo, Thomas M.
    Donnell, Jennifer
    Xia, Jing
    Rossi, Edmund A.
    Chang, Chien-Hsing
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01) : 196 - 203
  • [23] Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.
    Starodub, Alexander N.
    Ocean, Allyson J.
    Guarino, Michael J.
    Chuang, Ellen
    Shah, Manish A.
    Tagawa, Scott
    Picozzi, Vincent J.
    Thomas, Sajeve S.
    Maliakal, Pius P.
    Wegener, William A.
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [24] SN-38 antibody-drug conjugates as a novel platform for solid cancer therapy: preclinical science
    Goldenberg, David M.
    Cardillo, Thomas M.
    Sharkey, Robert M.
    McBride, William J.
    Rossi, Edmund A.
    Chang, Chien-Hsing
    Govindan, Serengulam V.
    CANCER RESEARCH, 2014, 74 (19)
  • [25] IMMU-130, a unique antibody-drug conjugate (ADC) of SN-38 targeting CEACAM5 antigen: Preclinical basis for clinical activity in metastatic colorectal cancer (mCRC).
    Govindan, Serengulam V.
    Cardillo, Thomas M.
    Rossi, Edmund A.
    McBride, William J.
    Sharkey, Robert M.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [26] IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results
    Goldenberg, David M.
    Vahdat, Linda T.
    Starodub, Alexander N.
    Bardia, Aditya
    Chuang, Ellen
    Moroose, Rebecca L.
    Diamond, Jennifer R.
    Sharkey, Robert M.
    Maliakal, Pius P.
    Hamburger, Steven A.
    Ocean, Allyson J.
    CANCER RESEARCH, 2015, 75
  • [27] IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies
    Segal, Neil H.
    Dotan, Efrat
    Berlin, Jordan D.
    Starodub, Alexander N.
    Guarino, Michael J.
    Saltz, Leonard B.
    Maliakal, Pius P.
    Govindan, Serengulam V.
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2014, 74 (19)
  • [28] IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Zalath, Maria B.
    Rossi, Diane L.
    Wang, Yang
    Chang, Chien-Hsing
    Goldenberg, David M.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01) : 150 - 160
  • [29] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results
    Bardia, Aditya
    Vahdat, Linda T.
    Diamond, Jennifer
    Kalinsky, Kevin
    O'Shaughnessy, Joyce
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Tolaney, Sara M.
    Santin, Alessandro D.
    Abramson, Vandana
    Shah, Nikita C.
    Govindan, Serengulam V.
    Maliakal, Pius
    Sharkey, Robert M.
    Wegener, William A.
    Goldenberg, David M.
    Mayer, Ingrid A.
    CANCER RESEARCH, 2018, 78 (04)
  • [30] Initial results of a new antibody-drug conjugate (ADC), IMMU-130 (labetuzumab-SN38), in patients with metastatic colorectal cancer (mCRC)
    Segal, N. H.
    Verghis, J.
    Govindan, S.
    Maliakal, P.
    Sharkey, R. M.
    Wegener, W. A.
    Goldenberg, D. M.
    Saltz, L. B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S545 - S546
12345